Sign in Subscribe
Cancer

Blocking Inhibitory Receptors Enhances Tumor Immunity in Gastric Cancer

Strategic Insights

— 1 min read

Pioneering research by investigators at Tehran University of Medical Sciences has made significant progress in understanding the role of inhibitory receptors in the treatment of gastric cancer. By blocking the NK group-2 member-A (NKG2A) receptor, researchers have demonstrated the enhancement of tumor immunity in natural killer (NK) cells, paving the way for innovative cancer therapies. This groundbreaking study has successfully utilized the combination of anti-NKG2A antibody-pretreated NK cells with IgG1 antibody (cetuximab) in patients with advanced gastric adenocarcinoma, showcasing the feasibility and safety of this treatment approach.

Key Takeaways:

  • The research found that blocking the inhibitory receptor NK group-2 member-A (NKG2A) enhances tumor immunity in natural killer (NK) cells, making it a promising target for cancer therapy.
  • The combination treatment of anti-NKG2A antibody-pretreated NK cells with cetuximab was well-tolerated and demonstrated significant reduction in tumor size and CA 19-9 levels in patients with advanced gastric adenocarcinoma.
  • All three patients in the study showed overall decreases in tumor size and CA19-9 level 4 weeks after combination therapy, indicating the effectiveness of the treatment.
  • Two patients showed progressive disease after 12 weeks, but the treatment remained safe and feasible.
  • The researchers concluded that their study demonstrated the safety and feasibility of infusing high doses of anti-NKG2A pretreated NK cells combined with cetuximab in patients with GAC.

Statistics:

  • 3 patients enrolled in the study, all of whom were unresectable and locally advanced gastric adenocarcinoma patients.
  • The treatment involved 3 times adoptive administration of anti-NKG2A pretreated NK cells at doses of 7×10^8 cells/injection at 5-day intervals.
  • CA 19-9 levels decreased in all three patients 4 weeks after combination therapy.
  • Tumor size decreased in all three patients 4 weeks after combination therapy.
  • Two patients showed progressive disease after 12 weeks.

Sources:

  • Research article: "Safety and Feasibility of Blockade of NK Group-2 Member-A Receptor in Natural Killer Cells Combined with Cetuximab Antibody in Patients with Advanced Gastric Adenocarcinoma", published in Advanced Pharmaceutical Bulletin, 2025, 15(1): 143-153.
  • Publisher: Tabriz University of Medical Sciences.
  • DOI: 10.34172/apb.43859.
  • Contact information: Maryam Samareh-Salavatipour, Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Read more